France to invest €670 million euros for Genomics and Personalized Medicine

Government of France Announce plans to invest €670 million euros or ($760.8 million) for Genomics and Personalized Medicine which will see it establish 12 genome sequencing centers and two national centers for genomic expertise and data analysis. The program would initially focus on cancer, diabetes and rare diseases but after 2020 would expand to include common diseases.

This investment by France follows the release on Wednesday of a report by medical experts examining the possibility of France widening access to genetic medicine within 10 years. A key objective in the report for the first 10 years of the programme is to prepare for the integration of genomic medicine into the normal course of patient care in the country, which means sequencing about 235,000 genomes per year by 2020.

Health Minister Marisol Touraine said Investment in the five year initiative will also come from industry. He also expected Companies like Google, Amazon, Apple and Facebook are interested in the growing genomic medicine sector

Several European countries have already begun to integrate genomic medicine into their health systems and there are large scale genomic initiatives in the UK, US and China. China has even recently announced a Precision Medicine Cloud



challenge 4 Indian Clinical Research outsourcing,CROs and Pharma R&D because Indians are genetically not single large population

challenge 4 Indian Clinical Research outsourcing, R&D plans because of a new discovery that Indians are genetically not single large population

“Drug companies engaged in clinical trails could be worried as our research shows that many groups in modern India descend from a small number of founding individuals. A common drug may not be the answer, considering the genetic variation in the Indian population. For instance, medicines tested on the Western population may not be effective on the Indian population,” said Lalji Singh, former director of the Centre for Cellular and Molecular and Biology (CCMB) who has co-authored the research findings on Reconstructing the Indian Population History, said on Thursday.

The work, published in the latest issue of Nature, has medical implications for people of Indian descent. More than three-fourths of India’s over one billion people are burdened with genetic disorders. The study shows that Indians have been genetically different from other groups and this could be a major cause of recessive diseases. The incidence of genetic diseases among Indians is, therefore, different from the rest of the world.

That could spell bad news for Clinical Research Outsorucing to India and Indian CRO companies, FDA can request for Pharmacogenomics supplementary data to prove that, Results of clinical trial are applicable to American populations.

“Drug trials should take into account diseases that are specific to the population,” said Lalji. A senior official of a top Indian drug-maker who did not wish to be identified said that pharma companies, the world over, are alive to the issue as the success of clinical trails and the efficacy of a drug hinges on the gene pool.

Ofcourse they knew about it all the time, Indian Ayruvedic medicine was aware that all humans canot be treated for the sames diseases with same treatment, more than 1000 years ago.

The article is available at Nature Magazine

IBM wants to sweeten chocolate the genomic style

Dont get your imagination run wild, you IBM machine not going to make Chocolates. Mars and IBM are to combine scientific and research resources with the US Department of Agriculture-Agricultural Research Service (USDA-ARS) in an attempt to sequence and analyse the entire cocoa genome.

IBM said in a statement that the combined effort could benefit more than 6.5 million farmers worldwide and help sustain the supply of chocolate

IBM has produced a video promotion of the Cocoa Genome project which is available on YouTube

Genetic testing impacts life insurance policies

The Association of British Insurers (ABI) has suspended the use of predictive genetic testing until the year 2014. allowing consumers to continue taking out cover without disclosing the adverse results of tests to predict a predisposition to cancer or heart disease.

Does that mean they will discriminate us later

Did they never heard of Genetic Information Nondiscrimination Act (GINA) the rule signed by US prsident with the intention of that will protect Americans against discrimination based on their genetic information when it comes to health insurance and employment.

Stephen Haddrill, the ABI’s Director General, said:

“The moratorium on the use of predictive genetic test results works well for consumers. It means people can insure themselves and their families, even if they have had an adverse result from a predictive genetic test. The moratorium has proved effective since its introduction in 2001 and can now continue

The moratorium was established in 2001 and covers policies worth up to £500,000 for life insurance, £300,000 for critical illness insurance and £30,000 a year for income protection insurance. The extension leaves consumers free to apply for cover up to these levels without advising an insurance company of the adverse results of any predictive genetic test they have taken.

According to the ABI, around 3% of policies sold in the UK are above these limits and in these cases, insurers can request predictive genetic tests but only if the tests are approved by an independent Government committee.

So far, the only test that has been approved in this way is for Huntington’s disease, for life cover over £500,000.The ABI has updated its consumer guide “Insurance and genetics: what you need to know”, which can be downloaded from its website. It will commence the next review of the moratorium in 2011

%d bloggers like this: